Alogliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Alogliptin Benzoate was developed by Syrrx Inc..
The API has now reached off-patent status, after being launched in 2013.

The information provided above is sourced from Chemrobotics PharmaVetPat https://chemroboticspharma.com/pharmVetPat
to find out more, including patent landscape and routes of synthesis, please contact our sales team.

For enquiries regarding more detailed trade data of Alogliptin Benzoate and many others, contact info@pharmacheminvestor.com